Table 2.

Global and Syk-specific tyrosine phosphorylation

Patient
no.
VH gene statusCD38 statusPhosphorylation
with anti-IgM*
Fold rise in Syk
phosphorylation
1Unmutated+Yes3
2Unmutated+Yes4
3Unmutated+Yes3
4Unmutated+Yes3
5Unmutated+Yes3
6Unmutated+No0
7Unmutated+Yes3
8Unmutated+No0
9Unmutated+Yes3
10Unmutated+No0
11UnmutatedYes2.5
12UnmutatedYes2
13UnmutatedYes2
14UnmutatedYes2
15UnmutatedYes2
16Mutated+No0
17Mutated+No0
18Mutated+Yes5
19Mutated+Yes2
20Mutated+Yes4
21Mutated+Yes3.5
22Mutated+No0
23MutatedNDYes4
24MutatedNo0
25MutatedNo1.5
26MutatedNo0
27MutatedNo0
28MutatedNo0
29MutatedNo0
30MutatedNo0
31MutatedNo0
32MutatedNo0
33MutatedNo0
34MutatedNDND0
35MutatedND0
36MutatedND1.8
37MutatedND0
38MutatedND0
39MutatedNDND0
40MutatedND1.3
  • The VH gene and CD38 expression status are shown. Samples with CD38 expression on more than 30% of CD5/CD19 double-positive cells were considered positive.

  • ND indicates not determined.

  • * CLL samples with a visible increase in global tyrosine phosphorylation in anti-IgM–stimulated cells relative to control antibody–treated cells were considered to be responsive to anti-IgM.

  • Fold increase in tyrosine phosphorylated Syk in anti-IgM–treated cells relative to control antibody–treated cells.